These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2908096)

  • 1. Report on schizophrenia of the American College of Neuropsychopharmacology. The Ad Hoc Committee on Schizophrenia.
    Friedhoff AJ; Kane J; Klerman G; Talbot J
    Neuropsychopharmacology; 1987 Dec; 1(1):89-99. PubMed ID: 2908096
    [No Abstract]   [Full Text] [Related]  

  • 2. [8th symposium of the Workshop for Neurospychopharmacology and Pharmacopsychiatry (AGNP) at Nuremberg, 26-29 October 1977. Pathophysiology and psychopharmacology of schizophrenic psychoses. Proceedings].
    Arzneimittelforschung; 1978; 28(9):1481-538. PubMed ID: 38805
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemodialysis and schizophrenia. Seventeenth Annual Meeting of the American College of Neuropsychopharmacology, Maui, Hawaii, 11--13 December 1978. Proceedings.
    Psychopharmacol Bull; 1979 Oct; 15(4):13-24. PubMed ID: 42102
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary on: "Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia." Psychopharmacology (1980) 72:17-19.
    Angrist B; Rotrosen J; Gershon S
    Psychopharmacology (Berl); 2001 Nov; 158(3):219-21. PubMed ID: 11713609
    [No Abstract]   [Full Text] [Related]  

  • 5. Psychopharmacology of schizophrenia in children and adolescents.
    Carlisle LL; McClellan J
    Pediatr Clin North Am; 2011 Feb; 58(1):205-18, xii. PubMed ID: 21281857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bridging pharmacology and neurodevelopment in schizophrenia.
    Kato T
    Int J Neuropsychopharmacol; 2007 Dec; 10(6):713-6. PubMed ID: 17651523
    [No Abstract]   [Full Text] [Related]  

  • 7. The 18th annual meeting of the Canadian College of Neuropsychopharmacology in Association with the Japanese Society of Neuropsychopharmacology. Vancouver, Canada, June 4-7, 1995.
    Boksa P; Gibson C; Welner S
    J Psychiatry Neurosci; 1995 Nov; 20(5):340-4. PubMed ID: 8527420
    [No Abstract]   [Full Text] [Related]  

  • 8. About the American College of Neuropsychopharmacology.
    Ray OS
    Acad Psychiatry; 2007; 31(2):122-4. PubMed ID: 17344449
    [No Abstract]   [Full Text] [Related]  

  • 9. Cognitive neuroscience and schizophrenia: translational research in need of a translator.
    Cohen JD; Insel TR
    Biol Psychiatry; 2008 Jul; 64(1):2-3. PubMed ID: 18549873
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenetics in psychiatry satellite meeting at the American College of Neuropsychopharmacology, 2000.
    Malhotra AK; Kennedy JL; Collier DA; Rietschel M
    Neuropsychopharmacology; 2002 Jan; 26(1):123-7. PubMed ID: 11795239
    [No Abstract]   [Full Text] [Related]  

  • 11. The Simon Bolivar Lecture: American Psychiatric Association. Some thoughts on the current status of the schizophrenic group of illnesses: treatment, research and social aspects.
    Sarwer-Foner GJ
    Psychiatr J Univ Ott; 1983 Jun; 8(2):1-16. PubMed ID: 6137015
    [No Abstract]   [Full Text] [Related]  

  • 12. British Association for Psychopharmacology--2008 Summer Meeting.
    Jenkins TA
    IDrugs; 2008 Oct; 11(10):720-3. PubMed ID: 18828070
    [No Abstract]   [Full Text] [Related]  

  • 13. Psychopharmacology of the negative symptoms: current status and prospects for progress.
    Davis MC; Horan WP; Marder SR
    Eur Neuropsychopharmacol; 2014 May; 24(5):788-99. PubMed ID: 24252823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schizophrenia.
    Roberson C
    Ala Nurse; 2009; 36(2):6-8. PubMed ID: 19583113
    [No Abstract]   [Full Text] [Related]  

  • 15. Schizophrenia: recent advances in psychopharmacology.
    Sharma T
    Br J Hosp Med; 1996 Feb 21-Mar 5; 55(4):194-8. PubMed ID: 8777500
    [No Abstract]   [Full Text] [Related]  

  • 16. Are we still talking to our patients with schizophrenia?
    Keith SJ
    Am J Psychiatry; 2006 Mar; 163(3):362-4. PubMed ID: 16513853
    [No Abstract]   [Full Text] [Related]  

  • 17. Transcranial direct current stimulation (tDCS) improved psychomotor slowness and decreased catatonia in a patient with schizophrenia: Case report.
    Chen CW; Lin SH; Huang LC; Yang YK
    Kaohsiung J Med Sci; 2018 Jun; 34(6):360-362. PubMed ID: 29747782
    [No Abstract]   [Full Text] [Related]  

  • 18. Does atypical antipsychotic medication improve executive function in schizophrenia?
    Collie A; Maruff P; Snyder PJ
    Int J Neuropsychopharmacol; 2006 Oct; 9(5):629-30; author reply 631-2. PubMed ID: 16893492
    [No Abstract]   [Full Text] [Related]  

  • 19. Workshop on defining the significance of progressive brain change in schizophrenia: December 12, 2008 American College of Neuropsychopharmacology (ACNP) all-day satellite, Scottsdale, Arizona. The rapporteurs' report.
    Borgwardt SJ; Dickey C; Hulshoff Pol H; Whitford TJ; DeLisi LE
    Schizophr Res; 2009 Jul; 112(1-3):32-45. PubMed ID: 19477100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The schizophrenic mind.
    Begley S
    Newsweek; 2002 Mar; 139(10):44-51. PubMed ID: 11894588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.